Genmab
| Genmab A / S | |
|---|---|
| legal form | A / S |
| ISIN | DK0010272202 |
| founding | 1999 |
| Seat |
Copenhagen , Denmark
|
| management | Jan van de Winkel (President and CEO ) |
| Number of employees | 313 |
| sales | 3.03 billion DKK (405.4 million euros ) |
| Branch | biotechnology |
| Website | www.genmab.com |
| As of December 31, 2018 | |
Genmab is a Danish company in the field of red biotechnology . Genmab develops and produces antibodies for oncological therapy. The company was founded in Copenhagen in 1999 and went public in Copenhagen and Frankfurt in 2000. The IPO brought in 1.56 billion Danish kroner (around 209 million euros). Two years later, in 2002, the Frankfurt company was delisted again . There are several development and commercialization agreements with pharmaceutical companies such as Hoffmann-La Roche , GlaxoSmithKline and Novartis .
One antibody produced by Genmab is ofatumumab .
Individual evidence
- ↑ Genmab: Senior Leadership , accessed March 4, 2019.
- ↑ Genmab: Annual Report 2018 , accessed March 4, 2019.
- ↑ Genmab: Research and technology , accessed March 4, 2019.
- ↑ Genmab: History , accessed March 4, 2019.